Earnings Call · Q4 FY2025·2026-02-26

Q4 25EPS +100.00%*·Rev n/aQ3 25EPS +10.53%·Rev n/aQ2 25EPS 0.00%·Rev n/aQ1 25EPS -100.00%*·Rev n/a⚠ consensus missing

Anika Therapeutics, Inc. ANIK

Matthew Hall — Executive Director of Corporate Development and Investor Relations

Stephen Griffin — Chief Executive Officer

Ian McLeod — Chief Accounting Officer

+16.9%1d on move date+17.5% vs SPY3d+30.9%5d+31.3%

Research tier

Behavioral profile computed for 3 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more ANIK calls or request research access.

More ANIK calls Browse calls Request research access